NASDAQ:OTIC - Otonomy Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $3.70 +0.15 (+4.23 %) (As of 07/20/2018 04:55 AM ET)Previous Close$3.55Today's Range$3.55 - $3.7552-Week Range$2.80 - $21.15Volume149,600 shsAverage Volume344,047 shsMarket Capitalization$114.67 millionP/E Ratio-1.20Dividend YieldN/ABeta3.2 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California. Receive OTIC News and Ratings via Email Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:OTIC CUSIPN/A Webwww.otonomy.com Phone619-323-2200 Debt Debt-to-Equity RatioN/A Current Ratio16.24 Quick Ratio16.24 Price-To-Earnings Trailing P/E Ratio-1.20 Forward P/E Ratio-2.10 P/E GrowthN/A Sales & Book Value Annual Sales$1.24 million Price / Sales91.25 Cash FlowN/A Price / CashN/A Book Value$3.87 per share Price / Book0.96 Profitability EPS (Most Recent Fiscal Year)($2.97) Net Income$-90,130,000.00 Net Margins-6,316.88% Return on Equity-58.60% Return on Assets-53.72% Miscellaneous Employees53 Outstanding Shares30,580,000Market Cap$114.67 Otonomy (NASDAQ:OTIC) Frequently Asked Questions What is Otonomy's stock symbol? Otonomy trades on the NASDAQ under the ticker symbol "OTIC." How were Otonomy's earnings last quarter? Otonomy Inc (NASDAQ:OTIC) posted its earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.05. The biopharmaceutical company earned $0.27 million during the quarter, compared to analyst estimates of $0.46 million. Otonomy had a negative return on equity of 58.60% and a negative net margin of 6,316.88%. The business's quarterly revenue was down 1.1% on a year-over-year basis. View Otonomy's Earnings History. What price target have analysts set for OTIC? 4 brokers have issued 12-month price objectives for Otonomy's stock. Their forecasts range from $8.00 to $15.00. On average, they anticipate Otonomy's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 170.3% from the stock's current price. View Analyst Ratings for Otonomy. What is the consensus analysts' recommendation for Otonomy? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Otonomy? Otonomy saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 727,991 shares, a decline of 44.9% from the June 15th total of 1,321,378 shares. Based on an average daily trading volume, of 576,927 shares, the days-to-cover ratio is currently 1.3 days. Currently, 2.8% of the shares of the company are short sold. View Otonomy's Current Options Chain. Who are some of Otonomy's key competitors? Some companies that are related to Otonomy include Forty Seven (FTSV), Verrica Pharmaceuticals (VRCA), Dermira (DERM), Evelo Biosciences (EVLO), ZIOPHARM Oncology (ZIOP), Sinovac Biotech (SVA), Syros Pharmaceuticals (SYRS), Unum Therapeutics (UMRX), Achillion Pharmaceuticals (ACHN), American Brivision (Holding) (ABVC), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Savara (SVRA), Xeris Pharmaceuticals (XERS) and ProMetic Life Sciences (PFSCF). Who are Otonomy's key executives? Otonomy's management team includes the folowing people: Dr. Jay B. Lichter, Co-Founder & Chairman (Age 56)Dr. David Allen Weber, Pres, CEO & Director (Age 58)Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 56)Dr. Kathie M. Bishop, Chief Scientific Officer (Age 52)Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel Has Otonomy been receiving favorable news coverage? Press coverage about OTIC stock has been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a news sentiment score of 0.11 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 49.67 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. How do I buy shares of Otonomy? Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Otonomy's stock price today? One share of OTIC stock can currently be purchased for approximately $3.70. How big of a company is Otonomy? Otonomy has a market capitalization of $114.67 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe. How can I contact Otonomy? Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected] MarketBeat Community Rating for Otonomy (NASDAQ OTIC)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 194 (Vote Outperform)Underperform Votes: 143 (Vote Underperform)Total Votes: 337MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?